Source: International Congress 2015 – The immunology of allergic airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Claus Kroegel (Jena, Germany), Claus Kroegel, Martin Foerster, Kristin Lerche, Maryam Aalamian-Mattheis, Janett Happe, Anne Moeser, Stephanie Korn. Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations. Eur Respir J 2015; 46: Suppl. 59, 2561

Member's Comments

No comment yet.

Related content which might interest you: Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Assessment of serum magnesium level in patients with bronchial asthma Source: International Congress 2016 – Systemic biomarkers Year: 2016 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Evaluation of vitamin D in asthma: Its effect on inflammatory markers and clinical profile Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 Correlation between asthma control and serum levels of IL-33 in atopic asthma Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology Year: 2016 A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Laser acupuncture effects on serum immunoglobulin E in A topic bronchial asthma patients Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015